Name: LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock
Brand: LIXTE BIOTECHNOLOGY HOLDINGS
Rating: 1.5 (3 reviews)

LIXT Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

2 months ago - By: Benzinga - Mentions: SSKN ENTX GNPX DMAC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - By: ACCESS Newswire

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

3 months ago - By: ACCESS Newswire

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

3 months ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

3 months ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

3 months ago - By: Benzinga - Mentions: RMTI NEO CHEK RLMD ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: 24/7 Market News and LIXTE Biotechnology Holdings

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

3 months ago - By: 24/7 Market News and LIXTE Biotechnology Holdings

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

3 months ago - By: LIXTE Biotechnology Holdings and 24/7 Market News

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

3 months ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Provides Corporate Update

4 months ago - By: LIXTE Biotechnology Holdings and 24/7 Market News

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

4 months ago - By: LIXTE Biotechnology Holdings and 24/7 Market News

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

4 months ago - By: LIXTE Biotechnology Holdings and 24/7 Market News

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

4 months ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

5 months ago - By: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

5 months ago - By: Spartan Capital Securities, LLC

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering

5 months ago - By: Lixte Biotechnology Holdings, Inc.

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

5 months ago - By: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

5 months ago - By: Spartan Capital Securities, LLC

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock News

LIXT Latest News, Press Relases and Analysis

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

12 Health Care Stocks Moving In Friday's Intraday Session

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

LIXTE Biotechnology Holdings Provides Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement